How to buy Viking Therapeutics stock - 06 March

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Viking Therapeutics stock

Own Viking Therapeutics stock in just a few minutes.

Updated

Fact checked

Viking Therapeutics, Inc is a biotechnology business based in the US. Viking Therapeutics shares (VKTX) are listed on the NASDAQ and all prices are listed in US Dollars. Viking Therapeutics employs 18 staff and has a market cap (total outstanding shares value) of USD$508.6 million.

How to buy shares in Viking Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Viking Therapeutics. Find the stock by name or ticker symbol: VKTX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Viking Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Viking Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Viking Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Viking Therapeutics share price

Use our graph to track the performance of VKTX stocks over time.

Viking Therapeutics shares at a glance

Information last updated 2021-03-02.
52-week rangeUSD$3.26 - USD$10.09
50-day moving average USD$7.5889
200-day moving average USD$6.589
Wall St. target priceUSD$19.71
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.353

Buy Viking Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get two free stock valued between $2.50 and $250
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
TradeStation
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Tastyworks
$0
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Interactive Brokers
$0
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Viking Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Viking Therapeutics financials

Gross profit TTM USD$0
Return on assets TTM -9.86%
Return on equity TTM -15.15%
Profit margin 0%
Book value $3.337
Market capitalisation USD$508.6 million

TTM: trailing 12 months

Shorting Viking Therapeutics shares

There are currently 8.3 million Viking Therapeutics shares held short by investors – that's known as Viking Therapeutics's "short interest". This figure is 2.2% down from 8.5 million last month.

There are a few different ways that this level of interest in shorting Viking Therapeutics shares can be evaluated.

Viking Therapeutics's "short interest ratio" (SIR)

Viking Therapeutics's "short interest ratio" (SIR) is the quantity of Viking Therapeutics shares currently shorted divided by the average quantity of Viking Therapeutics shares traded daily (recently around 1.8 million). Viking Therapeutics's SIR currently stands at 4.52. In other words for every 100,000 Viking Therapeutics shares traded daily on the market, roughly 4520 shares are currently held short.

However Viking Therapeutics's short interest can also be evaluated against the total number of Viking Therapeutics shares, or, against the total number of tradable Viking Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Viking Therapeutics's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Viking Therapeutics shares in existence, roughly 110 shares are currently held short) or 0.1436% of the tradable shares (for every 100,000 tradable Viking Therapeutics shares, roughly 144 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Viking Therapeutics.

Find out more about how you can short Viking Therapeutics stock.

Viking Therapeutics share dividends

We're not expecting Viking Therapeutics to pay a dividend over the next 12 months.

Viking Therapeutics share price volatility

Over the last 12 months, Viking Therapeutics's shares have ranged in value from as little as $3.26 up to $10.09. A popular way to gauge a stock's volatility is its "beta".

VKTX.US volatility(beta: 1.76)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Viking Therapeutics's is 1.7567. This would suggest that Viking Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Viking Therapeutics overview

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. Viking Therapeutics, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site